Global Finance News
19 Aug 2026, 16:32
Alnylam Pharmaceuticals Stock Rises 3.3% as BMO Capital Initiates Coverage With $318 Target
Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are up about 3.3% after BMO Capital Markets initiated coverage of the biotechnology company with an Outperform rating.
BMO Capital analyst David Lebowitz set a $318 price target for Alnylam. Compared with the stock's current price of $236.21, the target implies approximately 35% upside, providing a bullish signal for the shares.
The positive initiation comes as Alnylam maintains a leading position in RNA interference (RNAi) therapeutics, a technology designed to silence disease-causing genes. The company has developed a commercial portfolio of RNAi medicines while continuing to expand its pipeline across cardiovascular, neurological and other serious diseases.
Alnylam's established RNAi platform and potential for additional indications give the company a differentiated position within the biotechnology sector. The 3.3% stock gain suggests investors are responding positively to BMO Capital's Outperform initiation and substantial implied upside in its $318 price target.
Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are up about 3.3% after BMO Capital Markets initiated coverage of the biotechnology company with an Outperform rating.
BMO Capital analyst David Lebowitz set a $318 price target for Alnylam. Compared with the stock's current price of $236.21, the target implies approximately 35% upside, providing a bullish signal for the shares.
The positive initiation comes as Alnylam maintains a leading position in RNA interference (RNAi) therapeutics, a technology designed to silence disease-causing genes. The company has developed a commercial portfolio of RNAi medicines while continuing to expand its pipeline across cardiovascular, neurological and other serious diseases.
Alnylam's established RNAi platform and potential for additional indications give the company a differentiated position within the biotechnology sector. The 3.3% stock gain suggests investors are responding positively to BMO Capital's Outperform initiation and substantial implied upside in its $318 price target.
